However, in a cohort which includes low grade gliomas [10], significant survival benefits were observed for patients with low EZH2, PHF19, CBX8 and PHC2 expression, and high CBX7, CBX6, RYBP and EZH1 expression (Figure S2). The gene discussed is CBX6; the disease is central nervous system cancer.